• Risk of intracranial hemorrhage (ICH) may differ between direct oral anticoagulants (DOACs).
Essentials
• Risk of intracranial hemorrhage (ICH) may differ between direct oral anticoagulants (DOACs).
• We compared the risk of ICH between DOACs using network meta-analysis.
• Dabigatran 110 mg and 150 mg were safer than rivaroxaban on Bayesian analysis.
• Dabigatran 110 mg ranked as the safest DOAC while rivaroxaban ranked last.
Summary. Background:
The comparative risk of intracranial hemorrhage (ICH) among direct oral anticoagulants (DOACs) (dabigatran, rivaroxaban, apixaban and edoxaban) remains unclear. Objective: To determine the difference in risk of ICH between DOACs. Methods: Seventeen randomized controlled trials (RCTs) were selected using PubMed/MEDLINE, EMBASE and CEN-TRAL (Inception, 31 December 2017). Estimates were reported as odds ratio (OR) with 95% credible interval (CR.I) in Bayesian network meta-analysis (NMA), and OR with 95% confidence interval (CI) in traditional meta-analyses. Relative ranking probability of each group was generated based on surface under the cumulative ranking curve (SUCRA). Results: In NMA of 116 618 patients from 17 RCTs (apixaban = 19 495 patients, rivaroxaban = 14 157 patients, dabigatran = 16 074 patients, edoxaban = 11 652 patients, and comparator = 55 315 patients), all DOACs were safer than warfarin for risk of ICH. Dabigatran 110 mg ranked as the safest drug (SUCRA, 0.85) and reduced the risk of ICH by 56% compared to rivaroxaban (OR, 0.44; 95% Cr.I, 0.22-0.82). Pairwise meta-analysis validated these findings, showing that DOACs were safer than warfarin (OR, 0.46; 95% CI, 0.35-0.59). Subgroup analysis showed that the benefit was present when DOACs were used in nonvalvular atrial fibrillation (NVAF) (OR, 0.51; 95% CI,
Introduction
Clinicians are frequently faced with the dilemma of choosing between several different anticoagulants for a variety of indications. Direct oral anticoagulants (DOAC) have been FDA approved for stroke prevention in nonvalvular atrial fibrillation (NVAF), treatment of venous thromboembolic disease (VTE), and VTE prophylaxis in certain circumstances. It is likely that all DOACs are not equal in terms of safety and some may be better suited than others for individual patients based on their risk factors for different complications.
Intracranial hemorrhage (ICH) is arguably the greatest safety concern with anticoagulation. Clinicians should be aware of potential differences in the risk of ICH when choosing an anticoagulant for patients who are perceived to be at high risk of ICH. Prior meta-analyses examining the risk of ICH with DOACs have restricted their analysis to data from trials in which NVAF or VTE was the indication for anticoagulation [1] [2] [3] [4] [5] [6] [7] [8] . We are not aware of any prior meta-analyses that have combined data from trials across indications or used data from trials in which VTE prophylaxis was the indication for anticoagulation. Furthermore, since the publication of these prior metaanalyses, new randomized controlled trials have been published and should be incorporated. Therefore, to provide a more comprehensive and updated assessment, we used pairwise and network meta-analysis to compare the risk of ICH between different anticoagulants in patients who received anticoagulation for NVAF, VTE and VTE prophylaxis.
Methods
This meta-analysis is conducted in accordance with Cochrane Collaboration guidelines [9] and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension statement for network metaanalyses [10] .
Search strategy
Two authors (SUK and FN) independently searched the electronic databases: Medline (Ovid SP, PubMed), EMBASE and CENTRAL (inception, 31 December 2017). Results were restricted to randomized controlled trials (RCTs), human subjects and full-text articles. There was no restriction on year of publication or language. The key search terms were: 'new oral anticoagulants', 'novel oral anticoagulants', 'direct oral anticoagulants', 'NOAC', 'DOAC', 'apixaban', 'rivaroxaban', 'dabigatran', 'edoxaban' and 'intracranial hemorrhage'. The search algorithm is provided in Supporting Information (Data S1). The electronic search was complemented by review of bibliographies of relevant articles. All the citations were downloaded into EndNote (Thompson ISI ResearchSoft, Philadelphia, Pennsylvania, USA). Duplicates were removed electronically as well as manually.
Study selection
Two independent reviewers (FN and CR) were involved in the screening process and any discrepancies were resolved by discussion or third party (ZW) review. Studies were eligible for inclusion if they met the following criteria: (i) phase II or III RCTs, (ii) compared rivaroxaban, apixaban, edoxaban or dabigatran with control, (iii) reported at least one clinical event of ICH, and (iv) were a full-text article. There was no restriction on indications, sample size, comorbidities, language or follow-up duration. We excluded trials where DOACs were assessed for either acute coronary syndrome [11] [12] [13] [14] [15] , stable coronary artery disease [16] or NVAF after percutaneous coronary intervention (PCI) [17, 18] . This is because in coronary artery disease patients, studies were designed to compare DOACs (with background antiplatelet therapy) with placebo, which had the potential of overestimating the bleeding tendency of DOACs. This aspect was validated in former meta-analyses [19, 20] . Similarly, in two trials of NVAF after PCI [17, 18] , DOACs with single or dual antiplatelet therapy (DAPT) were compared with triple therapy (warfarin plus DAPT). This approach could also lead to over-or underestimation of bleeding propensity of DOACs.
Quality assessment and data extraction
Data extraction was carried out independently by two authors (SUK and FN) using a prespecified data abstraction form. The following information was extracted: baseline characteristics, drugs and dosages, comparators, indications and follow-up duration. The data extraction (events, event rates, crude point estimate and sample size) was carried out for the single endpoint of ICH. When available, data abstraction was carried out from intention to treat analysis. When possible, adjusted estimates were acquired. The dosages used in American and European Union markets were considered. The data adjudication was performed by CR. Quality/risk bias assessment was carried out according to the Cochrane bias risk assessment scale and the assessment of risk was carried out at the study level (Table S1 ) [21] .
Statistical analysis
The Bayesian network meta-analysis (NMA) was carried out using winBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) and NetMetaXL 1.6.1 (Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada). All treatment groups were analyzed within a mixed treatment comparison framework using Bayesian statistical methods [22, 23] . The random effects model was adopted for interpretation of estimates. Because informative priors can improve modeling efficiency by providing solutions to computational issues, we ultimately applied predictive distributions (informative variance priors) to random effects analyses [24] .
For informative variance prior, all-cause mortality informative priors were selected based on pharmacological intervention with objective outcomes. For all the outcomes, convergence was achieved at 20 000 iterations and absence of autocorrelation was checked and confirmed. The convergence was assessed using the Brooks-GelmanRubin method and by checking whether the MCMC error is < 5% of the standard deviation of the effect estimates and between-study variance [25] . The zeros were adjusted using a continuity correction factor accounting for potential differences in sample size and centered around 0.5 [26] . Estimates were presented as odds ratio (OR) with 95% credible interval (Cr.I) ranging from 2.5th to 97.5th centiles of posterior distribution. Markov chain Monte Carlo (MCMC) modeling was used to estimate the relative ranking probability of each treatment group. Results are ranked based on SUCRA, where values of 90% depict 90% safety compared with other interventions. The heterogeneity [s 2 ] was interpreted as low (s 2 = 0.04), moderate (s 2 = 0.14) or high (s 2 = 0.40) [27] . The inconsistency was assessed by comparing the deviance residuals and DIC statistics in fitted consistency and inconsistency models. These are reported in a table in Figure S1 . We plot the posterior mean deviance of the individual data points in the inconsistency model against their posterior mean deviance in the consistency model to identify any loops in the treatment network with inconsistency [28] . Pairwise traditional analysis was performed to assess the consistency of NMA. Comprehensive meta-analysis software version 3.0 (Biostat, Englewood, NJ, USA) was used for the analysis. Estimates are presented as random effects OR with 95% confidence interval (CI). A P-value of 0.05 is set as significant. Heterogeneity was assessed using Q statistics with I 2 > 50% being consistent with a high degree of heterogeneity [21] . Initial primary analysis was carried out between DOACs and a control group (aspirin, warfarin and low-molecular-weight heparin [LMWH]), followed by various subgroup analyses to generate more robust evidence. Subgroup analyses were carried out based on the comparator (i.e. warfarin and LMWH), dosages of DOACs and the indication for anticoagulation.
Results
The initial search yielded 1896 articles; 973 were duplicates and 956 were excluded based upon the title, abstract, study design and/or intracranial hemorrhage outcome not being reported as a distinct outcome ( Fig. 1) . Seventeen articles [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] were selected for analysis (Table 1) . Six RCTs studied apixaban, four studied rivaroxaban, four studied dabigatran and three studied edoxaban. Seven RCTs studied NOACs for stroke prevention in NVAF, seven for treatment of acute VTE and three for VTE prophylaxis in either medically ill patients (2) or post-surgical patients (1).
Characteristics of included trials and risk of bias
Baseline characteristics of the RCTs included in the metaanalysis are summarized in Table S1 . Table S2 low-molecular-weight heparin (LMWH) and 2791 received aspirin (ASA). The mean time in therapeutic range (international normalized ratio, 2.0-3.0) for patients in the warfarin group was 61.9% (range, 55-65.3%). The mean age of all patients was 65.3 AE 6.9 years; 59.6% were male. Among the included trials, there was good homogeneity in terms of exclusion criteria that may affect the baseline risk of ICH, such as history of ICH or intracranial lesions predisposing to ICH (neoplasm, arteriovenous malformation and aneurysm) and thrombocytopenia (Data S1). No trial allowed use of dual-antiplatelet therapy and the majority placed restrictions on how much daily aspirin could be used concomitantly (Data S1). There was heterogeneity with regards to follow-up and treatment duration, with shorter treatment and follow-up periods in trials where patients were anticoagulated for VTE prophylaxis and longer periods in trials for stroke-prevention in NVAF. Trials were also heterogeneous in the number of patients included who had a history of cancer (Data S1).
Bayesian network meta-analysis
The NMA ranked dabigatran as the safest drug (SUCRA, 0.85), followed by edoxaban (SUCRA, 0.79), apixaban (SUCRA, 0.59) and rivaroxaban (SUCRA, 0.26) (Fig. 2) (Fig. 4) . Statistical heterogeneity was low (s 2 = 0.12).
Pairwise meta-analysis
Pairwise meta-analysis showed consistent superiority of dabigatran (OR, 0.36; 95% CI, 0.26-0.49; P < 0.001), edoxaban (OR, 0.38; 95% CI, 0.29-0.48; P < 0.001) and apixaban (OR, 0.46; 95% CI, 0.34-0.61; P < 0.001) over control (Fig. 5) . DOACs in general were associated with a significant 54% relative risk reduction compared with warfarin (OR, 0.46; 95% CI, 0.35-0.59; P < 0.001) (Fig. 6 ). There was no significant difference between DOACS and LMWH (OR, 0.59; 95% CI, 0.17-2.03; P = 0.40) (Fig. 6 ). Based on the indication for anticoagulation, DOACs were superior to control in reducing the risk of ICH in patients with NVAF (OR, 0.51; 95% CI, 0.38-0.68; P < 0.001) and VTE (OR, 0.32; 95% CI, 0.18-0.58; P < 0.001), whereas there was no significant difference in patients requiring VTE prophylaxis (OR, 0.71; 95% CI, 0.10-5.14; P = 0.73) (Fig. 7) .
Discussion
This meta-analysis of 17 RCTs enrolling 116 618 patients is the first to our knowledge to compare the risk of ICH among DOACs using data from across indications for anticoagulation, including trials for stroke prevention in NVAF, VTE prophylaxis and treatment of VTE. Bayesian NMA showed that all DOACs were safer when compared with warfarin but that no significant difference existed when compared with LMWH. NMA also showed that dabigatran 110 mg was the safest drug, whereas rivaroxaban ranked as the least safe DOAC. The pairwise meta-analysis showed that DOACs as a category significantly reduced the risk of ICH compared with warfarin by 54%. They reduced the risk when used for stroke prevention in NVAF by 49% and by 68% when used for treatment of VTE. The risk is not significantly reduced when used in the prevention of VTE. Our NMA showed that both dabigatran 110 mg and 150 mg reduce the risk of ICH compared with rivaroxaban. Some prior meta-analyses [4, 6, 7] had shown that this difference was significant with only the 110 mg dose of dabigatran. However, these older analyses had only the RE-LY and ROCKET-AF trials available for their comparisons. Other prior analyses [1, 3] did not find that dabigatran was safer than rivaroxaban, but they did not distinguish between dabigatran doses and used data from only the RE-LY, ROCKET-AF and J ROCKET-AF trials. Since these older meta-analyses, additional RCTs have been published. By including these, our meta-analysis provides the most up to date evidence and clarifies the discrepancies among the earlier analyses.
Only a few previously reported Bayesian analyses have included edoxaban to our knowledge. Both Fernandez et al. [2] and Tawfik et al. [8] showed that there was a significant reduction in ICH with the 'low-dose' but not the 'high-dose' of edoxaban when compared with rivaroxaban using data from ENGAGE-AF TIMI and ROCKET-AF. Subsequent RCTs (Hokusai-VTE [41] and Hokusai-VTE Cancer [45] ) have used only the 'high-dose' regimen, which is the approved dose currently in use. Our analysis included these trials and validated that the dose currently in use is not significantly different compared with rivaroxaban (Fig. 4) .
A prior Bayesian meta-analysis by Verdecchia et al. [46] published in 2015 used data from major trials in which DOACs were compared with warfarin for stroke prevention in NVAF (RE-LY, ROCKET-AF, ARISTO-TLE and ENGAGE AF). They also ranked the anticoagulants and, as in our analysis, found that dabigatran 110 mg was the safest DOAC and rivaroxaban the least safe DOAC with regards to ICH. They too found that warfarin ranked last, behind all DOACs. We did not include edoxaban 30 mg (which ranked as second best in their analysis) but we did include apixaban 2.5 mg (which ranked as second best in our analysis). Dabigatran 150 mg ranked third, apixaban 5 mg fourth and edoxaban 60 mg fifth in both analyses. Our study thus agrees with but also extends the findings of this earlier analysis by including more patients and more indications for anticoagulation.
The findings of our analysis have clinical implications as the differences among DOACs may help in choosing between them for patients who have an increased risk of ICH. Established independent risk factors for ICH on anticoagulation are increasing age, concomitant aspirin use, and prior stroke or transient ischemic attack [5, 47, 48] . Other risk factors identified include renal dysfunction, being Asian, Black or Latino, reduced serum albumin, reduced platelet count and increased diastolic blood pressure [5, 48] . Despite knowledge of established risk factors, validated scoring systems to estimate risk of ICH are lacking.
The mechanism behind reduced risk of ICH with DOACs as opposed to warfarin is not understood. One proposed theory is that whereas warfarin affects several clotting factors, the DOACs target only one clotting factor [1] . Other possible explanations are that dabigatran does not cross the blood-brain barrier and that rivaroxaban and apixaban are effluxed out of the brain by p-glycoprotein efflux pumps [49] . Interestingly, the incidence of intracranial hemorrhage has been shown to be less than with warfarin regardless of whether the location is intracerebral, subarachnoid or subdural [5] . Lopes et al. also showed that with apixaban, the risk of both traumatic and spontaneous intracranial hemorrhage is reduced The major strength of our analysis is the large sample size, robust methodology and consistency of the results in subgroup analyses and pairwise analyses. However, there are certain limitations inherent to any meta-analysis. First, network meta-analysis assumes that there is homogeneity between the studies compared. However, some degree of heterogeneity is inevitably introduced. In our study, heterogeneity that may impact results includes factors such as variable time in therapeutic ranges for the warfarin groups, varying rates of concomitant antiplatelet use, and a range of follow-up and duration of therapy. However, because of this it may also be argued that our results are descriptive of a larger proportion of the population requiring anticoagulation. Second, by definition, NMA generates results based on incorporation of direct and indirect evidence and therefore the results should be considered as hypothesis generating. Ranking analyses should be viewed from a descriptive rather an inferential approach.
In summary, this meta-analysis may aid clinicians in choosing an anticoagulant for patients who are at an increased risk of ICH. DOACs are categorically safer than warfarin in both the treatment of VTE and stroke prevention in NVAF. Among the DOACs, dabigatran and edoxaban may be the safest choices. Where available, dabigatran 110 mg might be considered above any other anticoagulant for the patient at increased risk of ICH. Addendum S. U. Khan and F. Nasir performed the literature search; Z. Wolfe, F. Nasir and C. R. Subramanian performed data extraction; S. U. Khan performed the statistical analysis; Z. Wolfe and S. U. Khan drafted the manuscript; B. Lash critically revised the manuscript.
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